Financial Performance - For the six months ended June 30, 2020, the group recorded revenue of approximately RMB 42,023,000, an increase of about 33.78% compared to the same period in 2019[3]. - The group achieved a profit before tax of approximately RMB 25,536,000, representing a growth of approximately 39.40% year-on-year[4]. - Basic earnings per share for the period were approximately RMB 2.22 cents, up about 42.31% from the same period in 2019[5]. - The total comprehensive income for the period was RMB 22,046,000, compared to RMB 15,490,000 for the same period in 2019[15]. - Total revenue for the six months ended June 30, 2020, increased by 33.78% compared to the same period in 2019, with PMS revenue growing approximately 32.83%[22]. - The group reported a basic earnings per share of approximately RMB 22,046,000 for the period, compared to RMB 15,490,000 in the same period of 2019[25]. - The company achieved a pre-tax profit of approximately RMB 25,536,000, compared to RMB 18,319,000 in the same period last year, with a net profit of approximately RMB 22,046,000, up from RMB 15,490,000[33]. Dividends - The board of directors proposed not to declare any dividend for the six months ended June 30, 2020[6]. - No dividends were recommended for the period, consistent with the previous year[29]. - The board of directors did not recommend the distribution of dividends for the six months ended June 30, 2020[38]. Assets and Liabilities - As of June 30, 2020, the group had total current assets of RMB 128,260,000, compared to RMB 106,465,000 as of December 31, 2019[11]. - The group’s net current assets increased to RMB 76,871,000 as of June 30, 2020, compared to RMB 54,743,000 at the end of 2019[11]. - The group’s non-current assets, including property, plant, and equipment, amounted to RMB 4,685,000 as of June 30, 2020[11]. - The group’s total equity increased to RMB 79,026,000 as of June 30, 2020, from RMB 56,980,000 at the end of 2019[11]. - The company’s leverage ratio decreased to approximately 1.13% as of June 30, 2020, down from 1.35% as of December 31, 2019, due to an increase in total assets while total borrowings remained unchanged[35]. - The company has no significant contingent liabilities as of June 30, 2020[45]. Revenue Sources - Revenue from post-listing medical clinical services, clinical research, medical liaison, and medical market services was approximately RMB 41,174,000, accounting for 97.98% of total revenue, up 32.83% from RMB 30,997,000 in the same period last year[33]. - Related party revenue accounted for approximately 28.86% of total revenue, amounting to RMB 12,130,000[22]. Business Development - The group established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[31]. - The group introduced two new business models: RWS-Therapy and D-CRCO, aimed at redefining research-based treatment and commercialization through digitalization[31]. - The company plans to enhance its market promotion capabilities and expand its market network, focusing on a full value chain business model in the local market[37]. - The group is committed to becoming a comprehensive service provider under an internet framework for medical terminal services[21]. Corporate Governance - The company has complied with the corporate governance practices as per the GEM Listing Rules, with some deviations noted regarding the separation of roles between the chairman and CEO[84]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[86]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors as of the agreement date[89]. Employee Information - The company employed 91 staff as of June 30, 2020, down from 153 employees as of December 31, 2019, with total employee compensation during the period amounting to approximately RMB 4,390,000[54]. Shareholder Information - As of June 30, 2020, Guo Xia holds a total of 123,851,941 shares, representing approximately 12.48% of the company's equity[58]. - Winsland Agents Limited, a major shareholder, holds 349,368,873 shares, accounting for 35.19% of the company's equity[61]. - Venturepharm Holdings Inc. owns 149,432,583 shares, which is about 15.05% of the company's equity[61]. - Bright Excel Assets Limited, a subsidiary of Venturepharm Holdings Inc., holds 91,915,181 shares, representing 9.26% of the company's equity[61]. Stock Option Plan - The stock option plan approved in June 2015 has a validity period of 10 years, allowing for the issuance of options until June 29, 2025[65]. - The maximum number of shares available for purchase under the stock option plan is limited to 30% of the issued shares[68]. - The total number of shares available for issuance under the share option plan is 80,667,166 shares, accounting for 8.13% of the total issued shares as of the interim announcement date[70]. - The maximum number of shares that can be issued to each eligible participant within any 12-month period is limited to 1% of the issued shares, unless approved by shareholders[70]. - No performance targets are required to be met before exercising options, unless decided by the board[71]. - The exercise price for options must be at least the higher of the closing price on the grant date or the average closing price over the five trading days prior to the grant date[76]. - The total number of options granted to directors and employees as of June 30, 2015, was 13,490,000, with a remaining balance of 13,430,000 options[81]. - The company has not granted, exercised, canceled, or let expire any other share options during the reporting period[82].

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (于開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二零年第一季度報告 截至二零二零年三月三十一日止三個月 第一季度報告 截至二零二零年三月三十一日止三個月 香港聯合交易所有限公司（「聯交所」）創業板（「創業板」）特色 創業板之定位,乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市 之市場.有意投資之人士應瞭解投資於該等公司之潛在風險,並應經過審慎周詳之考慮後方 作出投資決定. 由於在創業板上市公司之新興性質所然,在創業板買賣之證券可能會較於聯交所主機板買賣 之證券承受較大之市場波動風險,同時無法保證在創業板買賣之證券會有高流通量之市場. 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告之內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任. 本報告乃遵照聯交所創業板證券上市規則（「創業板上市規則」）之規定而提供有關中國醫 療集團有限公司（「本公司」）及其附屬公司（ ...

Financial Performance - For the nine months ended September 30, 2019, the group recorded revenue of approximately RMB 39,609,000, an increase of about 2.36% compared to the same period in 2018[7]. - The group's profit before tax for the same period was approximately RMB 18,276,000, reflecting a growth of about 2.70% year-over-year[8]. - Basic earnings per share for the nine months ended September 30, 2019, were approximately RMB 1.51 cents, up by about 2.01% from the previous year[9]. - The gross profit for the nine months was approximately RMB 29,843,000, compared to RMB 29,289,000 in the same period last year, indicating a slight increase[13]. - Operating profit for the nine months was approximately RMB 18,340,000, compared to RMB 17,851,000 in the previous year[13]. - The total comprehensive income for the nine months was approximately RMB 15,010,000, compared to RMB 14,714,000 in the same period last year[13]. - Revenue from post-market clinical services, clinical research, medical liaison, and medical market services amounted to RMB 34,478,000, accounting for 87.05% of total revenue[32]. - Administrative expenses increased by 4.14% year-on-year, totaling RMB 11,503,000 for the nine months ended September 30, 2019[24]. - The applicable income tax rate for the period was between 9% and 25%, with some subsidiaries benefiting from a preferential tax rate of 9% due to their location in tax incentive zones[26]. - The group anticipates significant positive impacts on revenue and profit from the approval of ongoing related transactions post-2019[33]. Corporate Governance - The company has not appointed a CEO, with daily operations managed by executive directors and senior management[54]. - The company has complied with the corporate governance code, except for the separation of roles between the chairman and CEO[54]. - Non-executive directors do not have specific terms of appointment but can retire in rotation as per company regulations[54]. - The company aims to encourage attendance of directors at shareholder meetings to enhance transparency and accountability[55]. - The company has made efforts to ensure that independent directors understand shareholder opinions by attending annual general meetings[55]. - The company adopted a code of conduct for securities trading by the board, complying with the GEM Listing Rules[56]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements for the nine months ending September 30, 2019, and confirmed compliance with applicable accounting standards[58]. - The board announced delays in publishing the 2018 annual results and report, constituting a violation of GEM Listing Rules[59]. - The company failed to timely publish the Q1 2019 results and report, further violating GEM Listing Rules[59]. Strategic Focus - The group aims to become a comprehensive service provider under an internet framework in the healthcare sector[17]. - The group is focused on providing integrated pharmaceutical services in China, including clinical research and medical marketing[17]. - The group is investing in enhancing marketing capabilities and expanding market networks, focusing on a full-value chain business model in the local market[33]. - There were no significant investments or capital asset plans disclosed beyond what has been announced[38]. - The group closely monitors foreign currency risks and will hedge as necessary, with most transactions denominated in RMB[39]. Shareholding Structure - William Xia GUO holds a total of 712,328,578 shares, representing 71.75% of the company's equity[49]. - Winsland Agents Limited, controlled by William Xia GUO, owns 348,828,873 shares, accounting for 35.14% of the equity[49]. - Venturepharm Holdings Inc. holds 149,432,583 shares, which is 15.05% of the equity[49]. - Bright Excel Assets Limited, fully owned by Venturepharm Holdings Inc., has 91,915,181 shares, representing 9.26% of the equity[49]. - As of September 30, 2019, no other individuals were reported to have a direct or indirect interest of 5% or more in the shares[51].

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零一九年中期報告 截至二零一九年六月三十日止六個月 二零一九年中期報告 截至二零一九年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市之市 場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決 定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較大之市 場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失 承擔任何責任。 本報告乃遵照聯交所 GEM 證券上市規則之規定而提供有關中國醫療集團有限公司（「 ...

IC El First China Health Group CHINA HEALTH GROUP INC. 中 國 醫 療 集 團 有 限 公 司 (Carrying on businees in Hong Kong as "萬全醫療集園" ) (以「萬全醫療無劃」名稱在香港嚴重張彥) (Hoorporatiod in the Caynie (andred liability) (Nock Code: 08225) 《 股份代號: 08225) Annual Report 2018 年報 ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2018 CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate companies to which a higher inve ...

Financial Performance - For the three months ended March 31, 2019, the group recorded operating revenue of RMB 16,344,000, an increase of 8.59% compared to RMB 15,051,000 for the same period in 2018[6] - The group reported a profit before tax of RMB 8,349,000 for the three months ended March 31, 2019, which is a 20% increase from RMB 6,958,000 in the same period of 2018[7] - Basic and diluted earnings per share for the three months ended March 31, 2019, were RMB 0.72, up 20% from RMB 0.60 in the same period of 2018[8] - The gross profit for the three months ended March 31, 2019, was RMB 12,451,000, compared to RMB 11,136,000 for the same period in 2018[16] - The net profit attributable to equity holders of the company for the three months ended March 31, 2019, was RMB 7,119,000, compared to RMB 5,914,000 for the same period in 2018[25] - Revenue from post-market medical clinical services, clinical research, medical liaison, and medical market services (PMS) amounted to RMB 15,392,000, accounting for 94.17% of total revenue[63] Expenses and Dividends - Administrative expenses for the three months ended March 31, 2019, were RMB 4,100,000, slightly down from RMB 4,196,000 in the same period of 2018[18] - The company did not recommend any dividend payment for the quarter ended March 31, 2019, consistent with the previous year[60] - Basic earnings per share were calculated based on a profit attributable to ordinary shareholders of approximately RMB 7,119,000, compared to RMB 5,914,000 for the same period in 2018[56] Corporate Governance and Management - The company has complied with the corporate governance code as per the GEM Listing Rules, with only minor deviations regarding the roles of the chairman and CEO[84] - The audit committee, consisting of three independent non-executive directors, is responsible for reviewing the company's financial reports and internal control systems[89] - The company has not appointed a CEO, and daily management is conducted by executive directors and senior management[86] - The company has established a securities trading code for directors, ensuring compliance with trading regulations[85] Shareholding Structure - William Xia Guo holds a total of 712,426,578 shares, representing 71.76% of the company's equity[81] - Winsland Agents Limited, controlled by William Xia Guo, owns 348,068,873 shares, accounting for 35.06% of the total equity[81] - Venturepharm Holdings Inc. holds 149,432,583 shares, which is 15.05% of the company's equity[81] - The company has a total of 123,009,941 shares held by William Xia Guo as a beneficial owner, which includes 10,974,000 shares from stock options[82] - As of March 31, 2019, there were no other individuals holding 5% or more of the company's issued share capital[82] Tax and Financial Policies - The applicable corporate income tax rate for the quarter was between 9% and 25%, with some subsidiaries benefiting from a preferential tax rate of 9% due to their location in tax incentive zones[57] - The company continues to adhere to the revised Hong Kong Financial Reporting Standards without significant changes to its accounting policies[49] Future Outlook and Investments - The company is optimistic about the approval of ongoing related transactions, which are expected to have a significant positive impact on revenue and profit[64] - The company is investing in enhancing marketing capabilities and expanding market networks, focusing on a full value chain business model in the local market[64] - There were no significant investments or capital asset plans disclosed beyond what has been announced by the company[70] Risk Management - The company closely monitors foreign currency risks and will hedge as necessary, with most transactions denominated in RMB[71] Other Information - The company has not disclosed any new product or technology developments in this report[5] - There is no mention of market expansion or acquisitions in the current report[5] - The company has converted all convertible bonds into 77,500,000 shares, eliminating the bondholders' rights to the convertible bonds[79]